Orudis Retard: Main Uses and Benefits

Orudis Retard is a therapeutic option used for managing symptoms associated with various inflammatory and painful conditions. As a formulation of ketoprofen, it is primarily intended to provide symptomatic relief from pain and inflammation.

Key areas of use include managing signs of several rheumatic disorders. It is indicated to address pain and swelling related to inflammatory arthritis, such as rheumatoid arthritis and ankylosing spondylitis. The medication is also utilized in the management of osteoarthritis to help relieve associated joint pain and stiffness.

Additionally, Orudis Retard is used to provide temporary relief for certain acute painful conditions. This can include managing pain following surgical procedures, providing support for soft tissue injuries, and addressing pain associated with acute gout attacks.

Patients considering this medication should consult an appropriate healthcare professional for guidance and to review the potential benefits and risks.

---

Quick Facts (Therapeutic Domain)

• Addresses: Pain, swelling, and inflammation.
• Management Support: Rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
• Acute Relief: Postoperative pain and acute gout.

Official Eligibility Profile for Orudis Retard

Regulatory documents define specific populations who are eligible for or restricted from using Orudis Retard (Ketoprofen sustained-release). This medicine is generally intended for adults and is restricted for use in younger age groups, with safety and effectiveness not established for pediatric patients under 18 years.

---

Absolute Contraindications

Use is strictly prohibited in several populations due to heightened risk, including:

• Patients with documented hypersensitivity to Ketoprofen or cross-sensitivity to aspirin/other NSAIDs.
• Patients with active peptic ulcers or active inflammatory gastrointestinal disease.
• Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Women who are 30 weeks gestation or later (the third trimester).
• Patients with severe, uncontrolled hepatic, renal, or cardiac impairment.

---

Restricted and Conditional Use

Use requires caution and often a lower dose for populations such as the elderly, patients with mild-to-moderate renal or hepatic impairment, and those with established cardiovascular disease. Furthermore, use is not recommended for women who are breastfeeding or actively attempting to conceive.

Interactions with other medicines and products

Official regulatory information describes several categories of medicines that interact with this product, primarily impacting bleeding risk and renal function.

Bleeding Risk and Hemostasis

The co-administration of this product with anticoagulants (such as warfarin) or other medicines that affect blood clotting requires close monitoring due to an increased potential for bleeding. Concomitant use with Aspirin (Acetylsalicylic acid) or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is generally not recommended due to a combined increase in adverse effects, especially in the gastrointestinal system.

Renal Function and Blood Pressure Medicines

This product may reduce the blood pressure-lowering effect of Diuretics (e.g., furosemide, thiazides) and certain high blood pressure medicines, including ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs). The combination of this product with these medicines, particularly in patients with reduced kidney function, increases the risk of developing renal failure. Patients taking diuretics must be closely monitored for signs of potential renal issues.

Other Important Interactions

Co-administration with Lithium can result in elevated plasma lithium levels, increasing the risk of toxicity, which necessitates careful observation. This product may also increase the serum levels and toxicity of Methotrexate. The use of this product with Probenecid is not generally recommended, as Probenecid can reduce the body’s ability to clear this medicine. Antacids containing magnesium or aluminum hydroxide do not interfere with the absorption of this product.

How Orudis Retard Works: Mechanism of Action

The active ingredient, Ketoprofen, interacts with specific molecular mechanisms to influence biochemical and physiological pathways, based on three core mechanistic domains.

---

Non-Selective Enzyme Inhibition

The primary action involves the non-selective, competitive inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. By blocking these key enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins—chemical mediators derived from the Arachidonic Acid Cascade. This action modifies the initial molecular steps that shape downstream systemic outcomes.

---

Influence on Peripheral and Central Signaling Pathways

This mechanism targets both the local tissue environment and the central nervous system. In the periphery, the reduction of prostaglandins directly decreases the excitability threshold of peripheral nociceptors. Centrally, the mechanism engages the hypothalamus by blocking prostaglandin-mediated signaling, which is a key factor in central thermoregulation.

---

Resulting Physiological Pathway Adjustment

By suppressing prostaglandin synthesis, the drug influences pathway activity. The mechanism results in a reduction of mediator-driven activity, resulting in physiological adjustments that include a decrease in localized vascular permeability and the normalization of the hypothalamic thermoregulatory set-point.

How to Use Orudis Retard

The administration of Orudis Retard, a sustained-release formulation of ketoprofen, follows specific administration guidelines. This formulation is for oral administration only. The primary dosing pattern for adults in maintenance therapy, such as for chronic rheumatic conditions, involves a single 200 mg dose taken once daily. The sustained-release design is not recommended for the management of acute pain episodes.

---

Administration Requirements

To ensure the controlled release of the active ingredient, the capsule or tablet must be swallowed whole with a full glass of water. The medication must not be crushed, chewed, or broken apart prior to ingestion, as this would compromise the intended once-daily dosing pattern. To mitigate potential gastrointestinal discomfort, the dose may be taken with food, milk, or antacids; however, this does not alter the total amount of medication absorbed. Furthermore, patients are typically instructed to remain upright for approximately ten minutes following administration.

---

Dosing Modifications

Standard dosage principles require the use of the lowest effective dose for the shortest duration necessary. Specific maximum daily doses are established for patient populations with impaired organ function. In cases of severe renal impairment or hepatic impairment characterized by low serum albumin, the maximum daily dose should be reduced to 100 mg. For elderly or debilitated patients, it is recommended that initiation begin with a lower dose.

Research Evidence / Overview of Studies for Orudis Retard

---

Research Evidence for Symptomatic Relief in Osteoarthritis

The research into ketoprofen in the context of conditions such as Osteoarthritis (OA) primarily involves short-term to intermediate-term Randomized Controlled Trials (RCTs). These studies were applied in research exploring how symptoms change over time and often compared the medication against a placebo or other standard medications. The outcomes monitored in these studies are patient-reported outcomes describing perceived discomfort, focusing on pain, joint stiffness, and measures of daily functioning or activity level.

Studies reported measurements of change in patient-reported pain scores, often using standardized scales to track symptom intensity or variability. However, long-term effects are not fully established. There is limited information for long-term outcomes specifically characterizing the effect of the sustained-release formulation (Orudis Retard) on functional well-being over many years.

---

Research Evidence for Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a condition characterized by fluctuating or episodic manifestations, and the research for ketoprofen in this area has utilized Controlled Clinical Trials. These trials were applied in studies examining patient-reported experiences and outcomes linked to inflammatory or irritative states, such as localized joint swelling and overall disease activity. Findings describe patterns observed in the studies related to changes in joint pain and swelling.

The evidence base often consists of data for the general ketoprofen active ingredient, and specific findings for the sustained-release form are less commonly cited in comprehensive reviews. Subgroup findings are uncertain, as dedicated, contemporary RCTs specifically evaluating the sustained-release formula against some of the newest treatments for RA in large populations are less commonly cited.

---

Understanding Research Gaps and Uncertainties

The typical follow-up durations were limited in many of the key efficacy trials for both OA and RA, often focusing on short-term relief over several weeks or months. Key limitations include the fact that follow-up durations were limited in many comparative studies, leading to limited information for long-term outcomes and durability of effect.

Research examining the sustained-release formulation in specific groups, such as pediatric populations or those who are pregnant, is limited. Furthermore, sample sizes were modest in some of the older or highly specific comparative trials, and evidence quality varies across studies.

Key Studies & References

1. Efficacy of Ketoprofen vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
2. Ketoprofen Extended-Release Capsules, USP 200 mg (FDA Drug Label)

Common questions about Orudis Retard (FAQ)

Q: What is the main difference between Orudis Retard and a regular painkiller like ibuprofen?

A: Both Orudis Retard (ketoprofen) and common painkillers like ibuprofen belong to the same pharmacological class, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and share a similar mechanism of action. The key difference is the formulation: Orudis Retard is a sustained-release capsule, which is specifically designed to release the active ingredient slowly over a longer period. This feature typically allows the medicine to be administered once daily for chronic conditions, which differs from immediate-release forms.

---

Q: Why is this specific version called 'Retard' and what does that mean for how the drug works?

A: The term 'Retard' signifies that the medicine is a sustained-release formulation. This means the active ingredient is released slowly and continuously into the body over time. This design allows the medicine to be taken once daily while maintaining its therapeutic effect, according to official product information.

---

Q: What makes Orudis Retard a 'sustained-release' or 'prolonged-release' medicine?

A: The product is manufactured with a specialized internal structure, such as coated granules or a matrix within the capsule, which physically controls the speed at which the ketoprofen is released and absorbed over many hours. This controlled-rate release is what distinguishes it as a prolonged-release medicine.

---

Q: How quickly should I expect to feel the pain relief after taking Orudis Retard?

• As a sustained-release formulation, Orudis Retard is designed to maintain consistent levels of medication in the body, which results in a delayed peak concentration compared to immediate-release forms. Regulatory documents state that this specific formulation is generally not intended for the rapid relief of sudden, acute pain episodes.

---

Q: How long does the effect of one capsule of Orudis Retard usually last?

A: Official dosing guidelines state that Orudis Retard is a sustained-release formulation intended for once-daily administration. This design allows the medicine to release the active ingredient slowly over approximately 24 hours to support day-long effects.

---

Q: Can people who are generally healthy but have occasional severe pain use this drug?

A: Official prescribing information indicates that the sustained-release formulation of Orudis Retard is typically intended for the maintenance treatment of chronic conditions, such as arthritis. Regulatory documents generally do not recommend this specific formulation for the management of isolated episodes of acute pain.

---

Q: Is Orudis Retard safe to use for a long period, or is it only for short-term use?

A: Official safety precautions, which are common to all NSAIDs, state that treatment involves using the lowest effective dose for the shortest possible duration necessary to achieve treatment goals. This is a regulatory caution against unnecessary, continuous long-term use.

---

Q: Can this medication cause lightheadedness or affect my ability to concentrate?

A: Official safety information indicates that side effects associated with the use of ketoprofen include common effects like dizziness and headache. Less common effects that have been reported include somnolence (drowsiness) and trouble concentrating.

---

Q: Is Orudis Retard available over-the-counter or does it require a prescription?

A: Orudis Retard is the commercial designation for a medicine containing 200 mg of ketoprofen sustained-release, which is classified as a prescription-only medicine in the United States and the European Union. It is not available without a prescription.

---

Q: Are there any known interactions between Orudis Retard and herbal supplements?

A: While official regulatory documents detail interactions with prescription medicines, they do not explicitly list interactions with specific herbal supplements. However, combining NSAIDs with herbal supplements known to affect blood clotting may increase the risk of adverse effects.

---

Q: Can I take other pain relievers while I am taking Orudis Retard?

A: Official warnings strongly advise against combining Orudis Retard with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including aspirin, due to the increased risk of side effects. The label does not provide explicit information on all other classes of pain relievers.

---

Q: Do official studies mention Orudis Retard's effect on heart health?

A: Yes, the official label includes a serious boxed warning about the potential for increased risk of cardiovascular thrombotic events, such as heart attack and stroke, which can be fatal. Regulatory information states this risk may increase with the duration of use.

---

Q: Does Orudis Retard make you feel drowsy or sleepy?

A: Official safety information lists somnolence (drowsiness) as a reported side effect, though it is not considered one of the most common events. Dizziness, which can also affect alertness, is listed as a common side effect.

---

Q: What is the maximum amount of time a person can safely use this medicine?

A: Official safety precautions advise using the medication for the shortest possible duration necessary to achieve the treatment goal. This regulatory statement is a caution against unnecessary long-term use.

---

Q: Is there a risk of becoming physically dependent on Orudis Retard?

A: Orudis Retard is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). According to regulatory and clinical classification, NSAIDs are not associated with the same risks of physical dependence or addiction as opioid pain medications.

---

Q: Are there common reasons why people stop taking Orudis Retard?

A: Data from clinical trials indicate that the most frequently reported reasons for stopping therapy are related to gastrointestinal side effects. These commonly include issues like dyspepsia (indigestion) and abdominal pain, which are typical of the NSAID class.

---

Q: Is there a specific time of day recommended for taking Orudis Retard?

A: Official instructions specify that the dose is taken once daily. While a specific time is not strictly mandated, official guidance suggests taking the dose with food or milk, as this may help minimize the potential for stomach discomfort.

---

Q: Does Orudis Retard affect blood sugar levels?

A: Official drug documents do not list an effect on blood sugar as a direct side effect. However, regulatory information states that ketoprofen can interact with certain antidiabetic medicines, which requires careful monitoring when the two are used together.

---

Q: Are there warnings about sun exposure while taking Orudis Retard?

A: Yes, official product information includes warnings about potential photosensitivity reactions, which is an increased sensitivity to sunlight. Patients are generally advised to take precautions, such as avoiding excessive sun or UV light exposure, while using the product.

---

Q: Does taking Orudis Retard with food affect how well it works?

A: Official instructions state that the medicine may be taken with food, milk, or antacids to help minimize potential stomach discomfort. Taking it with food is not stated to alter the overall amount of medication absorbed by the body.

---

Q: Does Orudis Retard interact with common blood pressure medications?

A: Regulatory documents describe interactions with several classes of high blood pressure medicines, including Diuretics, ACE Inhibitors, and Angiotensin II Receptor Blockers (ARBs). This product is described as potentially reducing the blood pressure-lowering effect of these medicines.

---

Q: Are there research studies that support the use of Orudis Retard for chronic back pain?

A: Official drug documents list the primary therapeutic indications for this medicine, which typically focus on inflammatory conditions such as Rheumatoid Arthritis and Osteoarthritis. Chronic back pain is not explicitly listed as an approved indication in the key summary documents.

---

Q: Are there any warnings about combining Orudis Retard with alcohol consumption?

A: Official warnings state that combining the medicine with alcohol may increase the risk of gastrointestinal adverse effects, including bleeding. This is due to the potential combined irritating effect on the lining of the stomach.

---

Q: Does Orudis Retard interact with Probenecid?

A: Official drug interaction summaries state that co-administration with Probenecid is generally considered a combination to be avoided. This is because Probenecid can lead to increased concentrations of ketoprofen in the blood, potentially raising the risk of side effects.

How to Store and Dispose of Orudis Retard?

Official Storage Requirements

Orudis Retard must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be kept in the container in which it was dispensed and must remain tightly closed.

Storage Factor	Official Requirement
Temperature	Controlled Room Temperature: 20 C to 25 C
Protection	Keep away from excess heat, moisture, and light.
Safety	Store out of the sight and reach of children.

Disposal Instructions

Official regulatory guidance requires disposal of the unused or expired medication to be done according to local regulations. This product is not recommended for flushing down the sink or toilet. The preferred method for discarding unused Orudis Retard is by utilizing a drug take-back program or consulting a pharmacist for guidance on proper pharmaceutical waste handling.